Connection
Paul Bunn to Pyridines
This is a "connection" page, showing publications Paul Bunn has written about Pyridines.
|
|
Connection Strength |
|
|
|
|
|
0.385 |
|
|
|
-
Hirsch FR, Bunn PA. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan; 2(1):19-21.
Score: 0.089
-
Peled N, Zach L, Liran O, Ilouze M, Bunn PA, Hirsch FR. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 2013 Dec; 8(12):e112-3.
Score: 0.089
-
Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 01; 119(13):2383-90.
Score: 0.085
-
Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55.
Score: 0.079
-
Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236.
Score: 0.022
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|